OIL 3.03% 16.0¢ optiscan imaging limited

Ann: Pre-clinical research product launch, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,928 Posts.
    lightbulb Created with Sketch. 311
    Coming 2nd Quarter 2017

    Optiscan is delighted to announce the official launch of its 2nd generation Preclinical Research product; ViewnVivo.
    ViewnVivo is a miniaturised fluorescence endomicroscope platform that brings the next generation of Optiscan’s incredible imaging capability and flexibility to Preclinical Research.
    Users of ViewnVivo can capture high resolution, real-time in vivo images with submicron detail and view them in stunning quality for faster Preclinical Research insights.
    ViewnVivo represents a significant improvement to the existing competitor’s product offering in the research market providing major benefits including:

     Stunning image quality
     Interactive and continuously variable imaging depth control
     Greater sensitivity for even better image capture
     Validated capability
     Miniaturised without sacrificing image resolution
     Real-time In Vivo insight
     Flexibility of operation
     No dedicated technician or facility required
     Self-calibration and simplicity ensures immediate usability
     Patented technology
     Acceleration of research capability
 
watchlist Created with Sketch. Add OIL (ASX) to my watchlist
(20min delay)
Last
16.0¢
Change
-0.005(3.03%)
Mkt cap ! $129.4M
Open High Low Value Volume
16.5¢ 16.5¢ 16.0¢ $463 2.89K

Buyers (Bids)

No. Vol. Price($)
1 46748 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.5¢ 46940 2
View Market Depth
Last trade - 12.18pm 02/12/2024 (20 minute delay) ?
OIL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.